PMID- 17938126
OWN - NLM
STAT- MEDLINE
DCOM- 20080619
LR  - 20181201
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 28
IP  - 21
DP  - 2007 Nov
TI  - TAXUS VI 2-year follow-up: randomized comparison of polymer-based 
      paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
PG  - 2578-82
AB  - AIMS: Drug-eluting stents (DESs) have shown to be effective in reducing in-stent 
      restenosis, although data relating to long-term experience in treating more 
      complex lesion subsets are limited. In order to assess the long-term safety and 
      clinical efficacy of the polymer-based moderate release (MR) paclitaxel-eluting 
      TAXUS MR stent in treatment of complex lesion subsets, we evaluated the 2-year 
      follow-up of TAXUS VI. METHOD AND RESULTS: TAXUS VI was a randomized multi-centre 
      study enrolling 446 patients with complex lesions, including small vessels in 28% 
      of patients and a mean lesion length of 20.6 mm. At 9-month follow-up, the use of 
      the TAXUS MR stent was highly effective, resulting in a significant 53% reduction 
      of the target vessel revascularization (TVR) rate (primary endpoint) from 19.4% 
      in the control group to 9.1% in the TAXUS group (P = 0.0027). Clinical follow-up 
      at 2 years post-stenting was available in 98.6% of the TAXUS group and 95.6% of 
      the control group. The incidence of major adverse cardiac event at 1- and 2-year 
      follow-up was 16.4% and 21.3% in the TAXUS group when compared with 22.5 and 
      25.1% in the control group, respectively. A significant difference in TVR was 
      maintained at 2-year follow-up (TAXUS 13.9%; control 21.9%; P = 0.0335). The 
      cumulative 1- and 2-year survival rates free from TVR were, respectively, 91.7 
      and 90.3% in the TAXUS group vs. 80.0 and 79.0% in the control group (log-rank P 
      < 0.001). The number of patients required to be treated with a TAXUS stent to 
      prevent one re-percutaneous coronary intervention at 2 years was 12.5. 
      CONCLUSION: Treatment of complex coronary lesions with the polymer-based MR 
      paclitaxel-eluting TAXUS MR stent is associated with a sustained clinical benefit 
      and low rates of TVR up to 2 years after device implantation.
FAU - Grube, Eberhard
AU  - Grube E
AD  - HELIOS Heart Center Siegburg, Siegburg, Germany. grubee@aol.com
FAU - Dawkins, Keith D
AU  - Dawkins KD
FAU - Guagliumi, Giulio
AU  - Guagliumi G
FAU - Banning, Adrian P
AU  - Banning AP
FAU - Zmudka, Krzysztof
AU  - Zmudka K
FAU - Colombo, Antonio
AU  - Colombo A
FAU - Thuesen, Leif
AU  - Thuesen L
FAU - Hauptman, Karl
AU  - Hauptman K
FAU - Marco, Jean
AU  - Marco J
FAU - Wijns, William
AU  - Wijns W
FAU - Popma, Jeffrey J
AU  - Popma JJ
FAU - Buellesfeld, Lutz
AU  - Buellesfeld L
FAU - Koglin, Joerg
AU  - Koglin J
FAU - Russell, Mary E
AU  - Russell ME
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20071014
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 0 (Polymers)
RN  - A74586SNO7 (Clopidogrel)
RN  - OM90ZUW7M1 (Ticlopidine)
RN  - P88XT4IS4D (Paclitaxel)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
CIN - Eur Heart J. 2007 Nov;28(21):2559-60. PMID: 17938127
MH  - Aspirin/administration & dosage
MH  - Clopidogrel
MH  - Coronary Artery Disease/mortality/*therapy
MH  - Coronary Restenosis/*prevention & control
MH  - Coronary Thrombosis/etiology
MH  - Drug-Eluting Stents/adverse effects/*standards
MH  - Epidemiologic Methods
MH  - Female
MH  - Fibrinolytic Agents/*administration & dosage
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Revascularization/methods
MH  - Paclitaxel/*administration & dosage
MH  - Platelet Aggregation Inhibitors/administration & dosage
MH  - Polymers/administration & dosage
MH  - Ticlopidine/administration & dosage/analogs & derivatives
EDAT- 2007/10/17 09:00
MHDA- 2008/06/20 09:00
CRDT- 2007/10/17 09:00
PHST- 2007/10/17 09:00 [pubmed]
PHST- 2008/06/20 09:00 [medline]
PHST- 2007/10/17 09:00 [entrez]
AID - ehm424 [pii]
AID - 10.1093/eurheartj/ehm424 [doi]
PST - ppublish
SO  - Eur Heart J. 2007 Nov;28(21):2578-82. doi: 10.1093/eurheartj/ehm424. Epub 2007 
      Oct 14.